We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Read MoreHide Full Article
Key Takeaways
PCRX stock fell 9.6% after preliminary Q4 revenues of $196.9M missed consensus estimates.
Exparel Q4 sales rose 5% to $155.8M, as 7% volume growth was offset by discounts.
Pacira BioSciences posted 2025 revenues of $726.4M, up 4% year over year but below the consensus.
Pacira BioSciences (PCRX - Free Report) reported preliminary, unaudited total revenues of $196.9 million for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of $199 million. The investors were disappointed by the poor performance, following which the stock declined 9.6% on Friday.
Preliminary Q4 Product Revenues Reported by PCRX
Pacira BioSciences recognizes product revenues from the sales of its three marketed drugs — Exparel, Zilretta and iovera.
Per the preliminary fourth-quarter results, Exparel’s net product sales were $155.8 million, which increased 5% from the year-ago quarter’s figure. The reported figure marginally beat the Zacks Consensus Estimate of $155 million, as well as our model estimate of $155.1 million. Per Pacira BioSciences, Exparel volume growth of 7% was partly offset by changes in vial mix and launch-related discounting tied to a new group purchasing organization partnership.
Exparel (bupivacaine liposome injectable suspension) is indicated in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
In the past six months, shares of Pacira BioSciences have gained 0.9% compared with the industry’s 21% growth.
Image Source: Zacks Investment Research
Preliminary fourth-quarter Zilretta net product sales came in at $33 million, which was relatively flat year over year. The reported figure missed the Zacks Consensus Estimate of $34.4 million as well as our model estimate of $35.7 million.
Zilretta is approved as an extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain. Pacira BioSciences completed the acquisition of Flexion Therapeutics in November 2021, following which the former began recognizing Zilretta sales.
Preliminary net product sales of iovera were $7 million, up 8% from the year-ago quarter. The figure missed the Zacks Consensus Estimate of $7.3 million and matched our model estimate. The iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis.
Preliminary fourth-quarter revenues generated from the sales of bupivacaine liposome injectable suspension to third-party licenses were $1.1 million compared with zero in the year-ago quarter.
PCRX’s Preliminary Full-Year 2025 Revenues
In 2025, Pacira BioSciences reported preliminary, unaudited total revenues of $726.4 million, up 4% year over year, which also missed the Zacks Consensus Estimate of 728.8 million.
Pacira expects to report its complete financial results for the fourth quarter and full-year 2025, along with the company’s financial guidance for 2026, later in the first quarter of 2026.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have decreased from 67 cents to 65 cents. Shares of FOLD have surged 128.8% over the past six months.
Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark on the other three occasions, delivering an average negative surprise of 20.21%.
Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have lost 32.8% over the past six months.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Indivior’s earnings per share for 2026 have risen to $2.85 from $2.60. Indivior stock has rallied 126.9% over the past six months.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Key Takeaways
Pacira BioSciences (PCRX - Free Report) reported preliminary, unaudited total revenues of $196.9 million for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of $199 million. The investors were disappointed by the poor performance, following which the stock declined 9.6% on Friday.
Preliminary Q4 Product Revenues Reported by PCRX
Pacira BioSciences recognizes product revenues from the sales of its three marketed drugs — Exparel, Zilretta and iovera.
Per the preliminary fourth-quarter results, Exparel’s net product sales were $155.8 million, which increased 5% from the year-ago quarter’s figure. The reported figure marginally beat the Zacks Consensus Estimate of $155 million, as well as our model estimate of $155.1 million. Per Pacira BioSciences, Exparel volume growth of 7% was partly offset by changes in vial mix and launch-related discounting tied to a new group purchasing organization partnership.
Exparel (bupivacaine liposome injectable suspension) is indicated in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.
In the past six months, shares of Pacira BioSciences have gained 0.9% compared with the industry’s 21% growth.
Image Source: Zacks Investment Research
Preliminary fourth-quarter Zilretta net product sales came in at $33 million, which was relatively flat year over year. The reported figure missed the Zacks Consensus Estimate of $34.4 million as well as our model estimate of $35.7 million.
Zilretta is approved as an extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain. Pacira BioSciences completed the acquisition of Flexion Therapeutics in November 2021, following which the former began recognizing Zilretta sales.
Preliminary net product sales of iovera were $7 million, up 8% from the year-ago quarter. The figure missed the Zacks Consensus Estimate of $7.3 million and matched our model estimate. The iovera system is a groundbreaking, FDA-approved, drug-free treatment that alleviates pain through cryoneurolysis.
Preliminary fourth-quarter revenues generated from the sales of bupivacaine liposome injectable suspension to third-party licenses were $1.1 million compared with zero in the year-ago quarter.
PCRX’s Preliminary Full-Year 2025 Revenues
In 2025, Pacira BioSciences reported preliminary, unaudited total revenues of $726.4 million, up 4% year over year, which also missed the Zacks Consensus Estimate of 728.8 million.
Pacira expects to report its complete financial results for the fourth quarter and full-year 2025, along with the company’s financial guidance for 2026, later in the first quarter of 2026.
Pacira BioSciences, Inc. Price and Consensus
Pacira BioSciences, Inc. price-consensus-chart | Pacira BioSciences, Inc. Quote
PCRX’s Zacks Rank & Stocks to Consider
Pacira BioSciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amicus Therapeutics (FOLD - Free Report) , CorMedix (CRMD - Free Report) , and Indivior (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 EPS have decreased from 67 cents to 65 cents. Shares of FOLD have surged 128.8% over the past six months.
Amicus Therapeutics’ earnings beat estimates in one of the trailing four quarters, missing the mark on the other three occasions, delivering an average negative surprise of 20.21%.
Over the past 60 days, 2026 EPS estimates for CorMedix have risen from $2.49 to $2.88. Shares of CRMD have lost 32.8% over the past six months.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.04%.
Over the past 60 days, estimates for Indivior’s earnings per share for 2026 have risen to $2.85 from $2.60. Indivior stock has rallied 126.9% over the past six months.
Indivior’s earnings beat estimates in three of the trailing four quarters and were in line in the remaining quarter, with the average surprise being 68%.